LenfantC.Heart research: Celebration and renewal. Circulation1997;96:3822–3823.
2.
LundgrenE, TerracioL, BorgTK.Adhesion of cardiac myocytes to extracellular matrix components. Basic Res Cardiol1985;80:69–74.
3.
WeberKT, JalilJE, JanickiJS, PickR.Myocardial collagen remodeling in pressure overload hypertrophy. A case for interstitial heart disease. Am J Hypertens1989;2:931–940.
4.
CarverW, MolanoI, ReavesTA, BorgTK, TerracioL.Role of the alpha 1 beta 1 integrin complex in collagen gel contraction in vitro by fibroblasts. J Cell Physiol1995;165:425–437.
5.
CaulfieldJB, BorgTK.The collagen network of the heart. Lab Invest1979;40:364–372.
6.
BorgTK, RubinK, LundgrenE, BorgK, ObrinkB.Recognition of extracellular matrix components by neonatal and adult cardiac myocytes. Dev Biol1984;104:86–96.
7.
RobbinsJR, McGuirePG, Wehrle-HallerB, RogersSL.Diminished matrix metalloproteinase 2 (MMP-2) in ectomesenchyme-derived tissues of the Patch mutant mouse: Regulation of MMP-2 by PDGF and effects on mesenchymal cell migration. Dev Biol1999;212:255–263.
8.
WeberKT, PickR, SilverMA, MoeGW, JanickiJS, ZuckerIH, ArmstrongPW.Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation1990;82:1387–1401.
9.
MannDL, SpinaleFG.Activation of matrix metalloproteinases in the failing human heart: Breaking the tie that binds. Circulation1998;98:1699–1702.
10.
GalisZS, SukhovaGK, LarkMW, LibbyP.Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest1994;94:2493–2503.
11.
WeberKT, PickR, JanickiJS, GadodiaG, LakierJB.Inadequate collagen tethers in dilated cardiopathy. Am Heart J1988;116:1641–1646.
12.
WeberKT, AnversaP, ArmstrongPW, BrillaCG, BurnettJCJr, CruickshankJM, DevereuxRB, GilesTD, KorsgaardN, LeierCV. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol1992;20:3–16.
13.
BishopJE.LaurentGJ.Collagen turnover and its regulation in the normal and hypertrophying heart. Eur Heart J1995;16(suppl C):38–44.
14.
CleutjensJP.The role of matrix metalloproteinases in heart disease. Cardiovasc Res1996;32:816–821.
15.
NagaseH.Matrix metalloproteinases. In:HooperNM, ed.Zinc Metalloproteinases in Health and DiseaseLondon: Taylor & Francis Ltd; 1996:153–204.
16.
EghbaliM, WeberKT.Collagen and the myocardium: Fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem1990;96:1–14.
17.
StockerW, GramsF, BaumannU, ReinemerP, Gomis-RuthFX, McKayDB, BodeW.The metzincins-topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases. Protein Sci1995;4:823–840.
RawlingsND, BarrettAJ.Evolutionary families of metallopeptidases. Methods Enzymol1995;248:183–228.
20.
Gomis-RuthFX, MaskosK, BetzM, BergnerA, HuberR, SuzukiK, YoshidaN, NagaseH, BrewK, BourenkovGP, BartunikH, BodeW.Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature1997;389:77–81.
21.
BordenP, HellerRA.Transcriptional control of matrix metalloproteinases and the tissue inhibitors of matrix metalloproteinases. Crit Rev Eukaryot Gene Expr1997;7:159–178.
22.
FreijeJM, Diez-ItzaI, BalbinM, SanchezLM, BlascoR, ToliviaJ, Lopez-OtinC.Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J Biol Chem1994;269:16766–16773.
23.
GrossJ.Collagen biology: Structure, degradation, and disease. Harvey Lect1974;68:351–432.
24.
MillerEJ, HarrisEDJr, ChungE, FinchJEJr, McCroskeryPA, ButlerWT.Cleavage of Type II and III collagens with mammalian collagenase: Site of cleavage and primary structure at the NH2-terminal portion of the smaller fragment released from both collagens. Biochemistry1976;15:787–792.
25.
HastyKA, PourmotabbedTF, GoldbergGI, ThompsonJP, SpinellaDG, StevensRM, MainardiCL.Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem1990;265:11421–11424.
26.
DevarajanP, MookhtiarK, Van WartH, BerlinerN. Structure and expression of the cDNA encoding human neutrophil collagenase. Blood1991;77:2731–2738.
27.
EnghildJJ, SalvesenG, BrewK, NagaseH.Interaction of human rheumatoid synovial collagenase (matrix metalloproteinase 1) and stromelysin (matrix metalloproteinase 3) with human alpha 2-macroglobulin and chicken ovostatin. Binding kinetics and identification of matrix metalloproteinase cleavage sites. J Biol Chem1989;264:8779–8785.
28.
NguyenQ, MurphyG, HughesCE, MortJS, RoughleyPJ.Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein. Biochem J1993;295:595–598.
29.
MurphyG, NguyenQ, CockettMI, AtkinsonSJ, AllanJA, KnightCG, WillenbrockF, DochertyAJ.Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem1994;269:6632–6636.
30.
MurphyG, CockettMI, WardRV, DochertyAJ.Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J1991;277:277–279.
31.
WoessnerJF.NagaseH. Matrix Metalloproteinases and TIMPs. Oxford: Oxford University Press; 2000.
32.
MaciasD, Perez-PomaresJM, Garcia-GarridoL, CarmonaR, Munoz-ChapuliR.Immunoreactivity of the ets-1 transcription factor correlates with areas of epithelial-mesenchymal transition in the developing avian heart. Anat Embryol (Berl)1998;198:307–315.
33.
MazzieriR, MasieroL, ZanettaL, MoneaS, OnistoM, GarbisaS, MignattiP.Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants. EMBO J1997;16:2319–2332.
34.
GalisZS, MuszynskiM, SukhovaGK, Simon-MorrisseyE, UnemoriEN, LarkMW, AmentoE, LibbyP.Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res1994;75:181–189.
35.
LibbyP, OrdovasJM, BirinyiLK, AugerKR, DinarelloCA.Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest1986;78:1432–1438.
36.
BarathP, FishbeinMC, CaoJ, BerensonJ, HelfantRH, ForresterJS.Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol1990;65:297–302.
37.
MurphyG, AtkinsonS, WardR, GavrilovicJ, ReynoldsJJ.The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci1992;667:1–12.
38.
LiottaLA, SteegPS, Stetler-StevensonWG.Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell1991;64:327–336.
39.
HeCS, WilhelmSM, PentlandAP, MarmerBL, GrantGA, EisenAZ, GoldbergGI.Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci U S A1989;86:2632–2636.
40.
Saarialho-KereUK, KovacsSO, PentlandAP, OlerudJE, WelgusHG, ParksWC.Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing. J Clin Invest1993;92:2858–2866.
41.
HolvoetP, CollenD.Thrombosis and atherosclerosis. Curr Opin Lipidol1997;8:320–328.
42.
ArroyoLH, LeeRT.Mechanisms of plaque rupture: Mechanical and biologic interactions. Cardiovasc Res1999;41:369–375.
43.
ZaltsmanAB, GeorgeSJ, NewbyAC.Increased secretion of tissue inhibitors of metalloproteinases 1 and 2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler Thromb Vasc Biol1999;19:1700–1707.
44.
HenneyAM, WakeleyPR, DaviesMJ, FosterK, HembryR, MurphyG, HumphriesS.Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A1991;88:8154–8158.
45.
ChesebroJH, ZoldhelyiP, FusterV.Pathogenesis of thrombosis in unstable angina. Am J Cardiol1991;682B–10B.
46.
JangIK, LassilaR, FusterV.Atherogenesis and inflammation. Eur Heart J1993;14(suppl K):2–6.
47.
LibbyP, SukhovaG, LeeRT, GalisZS.Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol1995;25:S9–S12.
48.
ShahPK, FalkE, BadimonJJ, Fernandez-OrtizA, MailhacA, Villareal-LevyG, FallonJT, RegnstromJ, FusterV.Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation1995;92:1565–1569.
49.
DaviesMJ, RichardsonPD, WoolfN, KatzDR, MannJ.Risk of thrombosis in human atherosclerotic plaques: Role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J1993;69:377–381.
50.
Stetler-StevensonWG, KrutzschHC, LiottaLA.Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem1989;264:17374–17378.
51.
GoldbergGI, MarmerBL, GrantGA, EisenAZ, WilhelmS, HeCS.Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci U S A1989;86:8207–8211.
52.
BrownDL, HibbsMS, KearneyM, LoushinC, IsnerJM.Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation1995;91:2125–2131.
53.
BiniA, MannKG, KudrykBJ, SchoenFJ.Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol1999;19:1852–1861.
54.
RekhterMD, HicksGW, BrammerDW, WorkCW, KimJS, GordonD, KeiserJA, RyanMJ.Animal model that mimics atherosclerotic plaque rupture. Circ Res1998;83:705–713.
55.
SappinoAP, SchurchW, GabbianiG.Differentiation repertoire of fibroblastic cells: Expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest1990;63:144–161.
56.
SunY, WeberKT.Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol1996;28:851–858.
57.
VrackoR, ThorningD.Contractile cells in rat myocardial scar tissue. Lab Invest1991;65:214–227.
58.
CampbellSE, JanickiJS, WeberKT.Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol1995;27:1545–1560.
59.
WeberKT.Extracellular matrix remodeling in heart failure: A role for de novo angiotensin II generation. Circulation1997;96:4065–4082.
60.
LangeRA, HillisLD.Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? Thrombolysis—the preferred treatment. N Engl J Med1996;335:1311–1312.
61.
LangeRA, HillisLD.Aggressive versus conservative therapy in unstable angina. Cardiol Clin1999;17:387–399.
62.
SchwartzRS, HolmesDRJr, TopolEJ.The restenosis paradigm revisited: An alternative proposal for cellular mechanisms. J Am Coll Cardiol1992;20:1284–1293.
63.
SchwartzRS, HuberKC, MurphyJG, EdwardsWD, CamrudAR, VlietstraRE, HolmesDR.Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol1992;19:267–274.
64.
DolleryCM, McEwanJR, HenneyAM.Matrix metalloproteinases and cardiovascular disease. Circ Res1995;77:863–868.
65.
StraussBH, RobinsonR, BatchelorWB, ChisholmRJ, RaviG, NatarajanMK, LoganRA, MehtaSR, LevyDE, EzrinAM, KeeleyFW.In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res1996;79:541–550.
66.
MorenoPR, BernardiVH, Lopez-CuellarJ, NewellJB, McMellonC, GoldHK, PalaciosIF, FusterV, FallonJT.Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation1996;94:3098–3102.
67.
WangH, KeiserJA.Expression of membrane-type matrix metalloproteinase in rabbit neointimal tissue and its correlation with matrix-metalloproteinase-2 activation. J Vasc Res1998;35:45–54.
68.
BendeckMP, ZempoN, ClowesAW, GalardyRE, ReidyMA.Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res1994;75:539–545.
69.
TyagiSC, LewisK, PikesD, MarcelloA, MujumdarVS, SmileyLM, MooreCK.Stretch-induced membrane type matrix metalloproteinase and tissue plasminogen activator in cardiac fibroblast cells. J Cell Physiol1998;176:374–382.
70.
FitzgibbonGM, KafkaHP, LeachAJ, KeonWJ, HooperGD, BurtonJR.Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol1996;28:616–626.
71.
LoscalzoJ.Vascular matrix and vein graft failure. Is the message in the medium? Circulation2000;101:221–223.
72.
GeorgeSJ, LloydCT, AngeliniGD, NewbyAC, BakerAH.Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation2000;101:296–304.
73.
WitteMB, ThorntonFJ, KiyamaT, EfronDT, SchulzGS, MoldawerLL, BarbulA.Metalloproteinase inhibitors and wound healing: A novel enhancer of wound strength. Surgery1998;124:464–470.
74.
LiYY, McTiernanCF, FeldmanAM.Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res1999;42:162–172.
75.
CleutjensJP, KandalaJC, GuardaE, GuntakaRV, WeberKT.Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol1995;27:1281–1292.
76.
CharneyRH, TakahashiS, ZhaoM, SonnenblickEH, EngC.Collagen loss in the stunned myocardium. Circulation1992;85:1483–1490.
77.
ZhaoMJ, ZhangH, RobinsonTF, FactorSM, SonnenblickEH, EngC.Profound structural alterations of the extracellular collagen matrix in postischemic dysfunctional (“stunned”) but viable myocardium. J Am Coll Cardiol1987;10:1322–1334.
78.
CleutjensJP, VerluytenMJ, SmithsJF, DaemenMJ.Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol1995;147:325–338.
79.
RohdeLE, DucharmeA, ArroyoLH, AikawaMA, SukhovaGH, Lopez-AnayaA, McClureKF, MitchellPG, LibbyP, LeeRT.Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation1999;99:3063–3070.
PfefferJM, PfefferMA.Angiotensin converting enzyme inhibition and ventricular remodeling in heart failure. Am J Med1988;84:37–44.
82.
BeckerRC, HochmanJS, CannonCP, SpencerFA, BallSP, RizzoMJ, AntmanEM.Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: Observations from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction 9 Study. J Am Coll Cardiol1999;33:479–487.
83.
HeitmillerR, JacobsML, DaggettWM.Surgical management of postinfarction ventricular septal rupture. Ann Thorac Surg1986;41:683–691.
84.
TopazO, TaylorAL.Interventricular septal rupture complicating acute myocardial infarction: From pathophysiologic features to the role of invasive and noninvasive diagnostic modalities in current management. Am J Med1992;93:683–688.
85.
EdwardsBS, EdwardsWD, EdwardsJE.Ventricular septal rupture complicating acute myocardial infarction: Identification of simple and complex types in 53 autopsied hearts. Am J Cardiol1984;54:1201–1205.
86.
MooreCA, NygaardTW, KaiserDL, CooperAA, GibsonRS.Postinfarction ventricular septal rupture: The importance of location of infarction and right ventricular function in determining survival. Circulation1986;74:45–55.
87.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med1993;329673–682.
88.
The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators [published erratum appears in N Engl J Med 1994;330516]. N Engl J Med1993;329:1615–1622.
89.
CrenshawBS, GrangerCB, BirnbaumY, PieperKS, MorrisDC, KleimanNS, VahanianA, CaliffRM, TopolEJ.Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation2000;101:27–32.
90.
CummingsRG, CaliffR, JonesRN, ReimerKA, KongYH, LoweJE.Correlates of survival in patients with postinfarction ventricular septal defect. Ann Thorac Surg1989;47:824–830.
PeuhkurinenK, RisteliL, JounelaA, RisteliJ.Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator. Am Heart J1996;131:7–13.
FosangAJ, NeamePJ, LastK, HardinghamTE, MurphyG, HamiltonJA.The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem1992;267:19470–19474.
95.
BonassarLJ, FrankEH, MurrayJC, PaguioCG, MooreVL, LarkMW, SandyJD, WuJJ, EyreDR, GrodzinskyAJ.Changes in cartilage composition and physical properties due to stromelysin degradation. Arthritis Rheum1995;38:173–183.
96.
HaroH, CrawfordHC, FingletonB, ShinomiyaK, SpenglerDM, MatrisianLM.Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest2000;105:143–150.
97.
HaroH, CrawfordHC, FingletonB, MacDougallJR, ShinomiyaK, SpenglerDM, MatrisianLM.Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. J Clin Invest2000;105:133–141.
98.
ThomasCV, CokerML, ZellnerJL, HandyJR, CrumbleyAJIII, SpinaleFG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation1998;97:1708–1715.
99.
TyagiSC, KumarS, VoelkerDJ, ReddyHK, JanickiJS, CurtisJJ.Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem1996;63:185–198.
100.
SpinaleFG, CokerML, ThomasCV, WalkerJD, MukherjeeR, HebbarL.Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: Relation to ventricular and myocyte function. Circ Res1998;82:482–495.
101.
DoeringCW, JalilJE, JanickiJS, PickR, AghiliS, AbrahamsC, WeberKT.Collagen network remodelling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res1988;22:686–695.
102.
SpinaleFG, CokerML, KrombachSR, MukherjeeR, HallakH, HouckWV, ClairMJ, KribbsSB, JohnsonLL, PetersonJT, ZileMR.Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function. Circ Res1999;85:364–376.
103.
CokerML, DoscherMA, ThomasCV, GalisZS, SpinaleFG.Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol1999;277H777–H787.
104.
LiYY, FeldmanAM, SunY, McTiernanCF.Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation1998;98:1728–1734.
105.
TyagiSC.Extracellular matrix dynamics in heart failure: A prospect for gene therapy. J Cell Biochem1998;68:403–410.
106.
McElmurrayJHIII, MukherjeeR, NewRB, SampsonAC, KingMK, HendrickJW, GoldbergA, PetersonTJ, HallakH, ZileMR, SpinaleFG. Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: Comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther1999;291:799–811.
107.
PyeritzRE, McKusickVA. The Marfan syndrome: Diagnosis and management. N Engl J Med1979;300772–777.
108.
RobertsWC, HonigHS.The spectrum of cardiovascular disease in the Marfan syndrome: A clinico-morphologic study of 18 necropsy patients and comparison to 151 previously reported necropsy patients. Am Heart J1982;104:115–135.
109.
MurdochJL, WalkerBA, HalpernBL, KuzmaJW, McKusickVA.Life expectancy and causes of death in the Marfan syndrome. N Engl J Med1972;286:804–808.
110.
ShoresJ, BergerKR, MurphyEA, PyeritzRE.Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med1994;330:1335–1341.
111.
DavidTE, FeindelCM, BosJ.Repair of the aortic valve in patients with aortic insufficiency and aortic root aneurysm. J Thorac Cardiovasc Surg1995;109:345–351.
112.
GottVL, GreenePS, AlejoDE, CameronDE, NaftelDC, MillerDC, GillinovAM, LaschingerJC, PyeritzRE.Replacement of the aortic root in patients with Marfan's syndrome. N Engl J Med1999;340:1307–1313.
113.
FranckeU, FurthmayrH.Marfan's syndrome and other disorders of fibrillin. N Engl J Med1994;330:1384–1385.
114.
PerejdaAJ, AbrahamPA, CarnesWH, CoulsonWF, UittoJ.Marfan's syndrome: Structural, biochemical, and mechanical studies of the aortic media. J Lab Clin Med1985;106:376–383.
115.
SeguraAM, LunaRE, HoribaK, Stetler-StevensonWG, McAllisterHAJr, WillersonJT, FerransVJ.Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation1998;98II331–II337.
116.
HayashiT, Stetler-StevensonWG, FlemingMV, FishbackN, KossMN, LiottaLA, FerransVJ, TravisWD.Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol1996;149:1241–1256.
117.
RamirezF, GayraudB, PereiraL. Marfan syndrome: New clues to genotype-phenotype correlations. Ann Med1999;31:202–207.
118.
ThompsonRW, BaxterBT.MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann N Y Acad Sci1999;878:159–178.
119.
CurciJA, MaoD, BohnerDG, AllenBT, RubinBG, ReillyJM, SicardGA, ThompsonRW.Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg2000;31:325–342.
KaiH, IkedaH, YasukawaH, KaiM, SekiY, KuwaharaF, UenoT, SugiK, ImaizumiT.Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol1998;32:368–372.
122.
KlappacherG, FranzenP, HaabD, MehrabiM, BinderM, PleschK, PacherR, GrimmM, PribillI, EichlerHG. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol1995;75:913–918.
123.
VincentiMP, ClarkIM, BrinckerhoffCE.Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum1994;37:1115–1126.
